Celcuity Inc. (NASDAQ: CELC) is a clinical-stage biotechnology company developing companion diagnostics and targeted therapies for cancer. Its lead candidate, gedatolisib, is a dual PI3K/mTOR inhibitor for HR+/HER2- breast cancer, currently in Phase 3 development. Celcuity integrates functional cell analysis with precision oncology to identify responsive patient subgroups. The company offers high-upside exposure to targeted cancer therapeutics and biomarker-driven clinical development.
Последние статьи по акциям